NASDAQ · COGT
Healthcare · Biotechnology
$32.74
Down-$0.67 (-2.01%)
Updated Sep 16, 2026, 12:25 PM
SID Score
4.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
COGT closed at $32.74 after 20 trading sessions, down 12.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $33.37 | $33.93 | $32.69 | $32.74 | 1.71M |
| Sep 14, 2026 | $33.42 | $33.575 | $32.85 | $33.41 | 1.44M |
| Sep 11, 2026 | $34.51 | $35.00 | $33.21 | $33.41 | 1.72M |
| Sep 10, 2026 | $33.50 | $34.19 | $33.07 | $34.08 | 2.26M |
| Sep 9, 2026 | $35.09 | $35.57 | $34.075 | $34.18 | 1.59M |
| Sep 8, 2026 | $34.16 | $35.75 | $33.90 | $35.28 | 2.24M |
| Sep 4, 2026 | $34.56 | $35.20 | $34.42 | $34.76 | 784.08K |
| Sep 3, 2026 | $34.90 | $35.14 | $34.06 | $34.95 | 1.27M |
| Sep 2, 2026 | $35.18 | $35.82 | $34.01 | $34.57 | 1.18M |
| Sep 1, 2026 | $34.48 | $34.99 | $34.30 | $34.68 | 1.48M |
| Aug 31, 2026 | $34.61 | $35.21 | $34.11 | $35.00 | 1.85M |
| Aug 28, 2026 | $36.66 | $36.845 | $34.53 | $34.67 | 1.77M |
| Aug 27, 2026 | $36.51 | $37.665 | $36.412 | $37.09 | 1.64M |
| Aug 26, 2026 | $36.49 | $37.12 | $36.282 | $36.72 | 1.06M |
| Aug 25, 2026 | $36.56 | $37.08 | $36.44 | $36.80 | 1.39M |
| Aug 24, 2026 | $36.75 | $37.115 | $36.07 | $36.23 | 1.21M |
| Aug 21, 2026 | $35.75 | $37.22 | $35.40 | $36.73 | 2.52M |
| Aug 20, 2026 | $36.31 | $36.695 | $34.91 | $35.31 | 1.94M |
| Aug 19, 2026 | $38.62 | $38.62 | $36.70 | $36.85 | 1.25M |
| Aug 18, 2026 | $37.32 | $38.314 | $37.01 | $37.40 | 1.15M |
The latest Smart Investors Daily articles mentioning COGT.
COGT research
Company profile and research snapshot.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| May 29, 2026 | Wedbush | Outperform | — |
| May 6, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 2, 2026
On September 1, 2026, Cogent Biosciences, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Agreement") with Hovione FarmaCiencia S.A. ("Hovione") to manufacture bezuclastinib
Benzinga · Aug 31, 2026
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a market capitalization
SeekingAlpha · Aug 27, 2026
Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Learn more about COGT stock here.
SeekingAlpha · Aug 23, 2026
Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COGT.
